

Ontario Public Drug Programs

Drug Submission Status
Updated: November 22, 2013

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Marcan Pharmaceuticals Inc.	Mar-Paroxetine	Paxil	paroxetine HCl hemihydrate	10mg	FC tablet	02411946
Mint Pharmaceuticals Inc.	Mint-Montelukast	Singulair	montelukast sodium	5mg	chewable tablet	02408635
Mint Pharmaceuticals Inc.	Mint-Montelukast	Singulair	montelukast sodium	10mg	FC tablet	02408643
Ranbaxy Pharmaceuticals Canada Inc.	Ran-Olanzapine ODT	Zyprexa Zydis	olanzapine	20mg	orally disintegrating tablet	02414120
Sterimax Inc.	Tetrabenazine Tablets	Nitoman	tetrabenazine	25mg	tablet	02410338

